Ionic Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Ionic Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-25,731	Closed	-$2.28M	–	336
2016 Q4	$2.28M	Sell	25,731 -1,269	-5%	-$115K	0.12%	181
2016 Q3	$2.6M	Sell	27,000 -33,300	-55%	-$3.17M	0.12%	166
2016 Q2	$5.17M	Buy	+60,300	New	+$5.41M	0.23%	95

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ionic Capital Management's IBB Position: Q1 2017 in Review

Ionic Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 25,731 shares — an estimated $2.28M sold.

Ionic Capital Management first reported a position in IBB in Q2 2016 and held it in 3 quarters. The position peaked at $5.17M in Q2 2016. 520 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

Ionic Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
Ionic Capital Management sold 25,731 iShares Biotechnology ETF shares in Q1 2017, an estimated $2.28M.
Ionic Capital Management first reported a position in iShares Biotechnology ETF in Q2 2016 and held it in 3 quarters.
Ionic Capital Management's iShares Biotechnology ETF position peaked at $5.17M in Q2 2016.
520 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Ionic Capital Management's 13F filing for Q1 2017, filed 15 May 2017.